About this trial
The main causes of chronic heart failure (CHF) are arterial hypertension and coronary artery disease, less often cardiomyopathy, pericarditis, metastatic myocardial lesions. It should be noted that up to 50% of patients have a preserved left ventricular ejection fraction (LVEF), while its prevalence is progressively increasing annually.
Acute decompensation of CHF is understood as a rapid increase in the severity of clinical manifestations (shortness of breath, severe arterial hypoxemia, the occurrence of arterial hypotension), which caused urgent medical treatment and emergency hospitalization in a patient already suffering from CHF. Decompensation of CHF requires intensification of treatment in order to stabilize the patient's condition. Strengthening diuretic therapy in addition to standard therapy helps to reduce edematous syndrome.
Eligibility criteria
Qualifiers
Men or women aged 18 years and older
Decompensated CHF NYHA II-IV, which required intravenous administration of diuretics
Any injection fraction of left ventricle*
Signed informed consent to participate in the study.
Disqualifiers
Acetazolamide therapy for a month before hospitalization.
The expected intravenous use of inotropes, vasopressors or sodium nitroprusside at any time of the study.
Exposure to nephrotoxic agents (e.g. contrast dye) is expected within the next 3 days.
Hypersensitivity to acetazolamide, other sulfonamides and / or components of the drug.
Trial design
Treatments tested in this trial
- Acetazolamide